Sarepta Therapeutics | SRPT - Cash And Equivalent


Sarepta Therapeutics reported $472.76M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
Agios Pharmaceuticals USD 128.55M 28.9M Sep/2026
Alnylam Pharmaceuticals USD 1.75B 46.02M Sep/2026
Amgen USD 13.19B 799M Sep/2026
BioCryst Pharmaceuticals USD 96.97M 58M Sep/2026
Biogen USD 1.3B 18.9M Sep/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Capricor Therapeutics USD 20.94M 84.49M Jun/2026
Daiichi Sankyo JPY 637.85B 188.04B Jun/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
Incyte USD 3.85B 127.8M Sep/2026
Insmed USD 396.56M 148.2M Sep/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Moderna USD 1.72B 185M Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
Novavax USD 222.46M 31M Sep/2026
Pfizer USD 1.82B 848M Sep/2026
PTC Therapeutics USD 508.89M 540.99M Sep/2026
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Sarepta Therapeutics USD 472.76M 98.39M Sep/2026
Tectonic Therapeutic USD 227.07M 9.83M Jun/2026
Ultragenyx Pharmaceutical USD 150M 25M Sep/2026
Vertex Pharmaceuticals USD 6.3B 1.55B Sep/2026